MedTrace Logo

Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib

NCT05007093 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-11-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of anlotinib in patients with locally advanced or metastatic differentiated thyroid cancer resistant to iodine therapy.

Conditions

  • DTC - Differentiated Thyroid Cancer

Interventions

DRUG

Anlotinib hydrochloride

If intolerance occurs, the dose can be downregulated

Sponsors & Collaborators

  • Yansong Lin

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2024-11-01
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05007093 on ClinicalTrials.gov